The discovery and development of medications to treat addiction and notably, cocaine
addiction, have been frustrated by both the complexity of the disorder and the lack of target …

At the present time, there are no drugs are approved in the US for the treatment of stimulant
abuse. Based on a diverse body of preclinical data, sometimes termed the “dopamine …

The dopamine transporter (DAT) is a target for the development of pharmacotherapies for a
number of central disorders including Parkinson's disease, Alzheimer's disease …

In an attempt to discover a cocaine‐abuse pharmacotherapeutic, extensive investigation has
been directed toward elucidating the molecular mechanisms underlying the reinforcing …

Stimulant drugs acting at the dopamine transporter (DAT), like cocaine, are widely abused,
yet effective medical treatments for this abuse have not been found. Analogs of benztropine …

The widely abused psychostimulant cocaine is thought to elicit its reinforcing effects
primarily via inhibition of the neuronal dopamine transporter (DAT). However, not all DAT …

The design, synthesis and pharmacological evaluation of novel dopamine transporter
ligands, based on Benztropine [30-(diphenylmethoxy) tropane], has been a focus of our …

There is a large unmet medical need for cocaine addiction treatments. Studies have
indicated that the dopamine transporter (DAT) is the primary biological target of cocaine, and …

Repeated administration of cocaine will cross-sensitize the locomotor response to a variety
of psychomotor stimulants. The ability of cocaine to cross-sensitize the locomotor effects of …

Despite intensive medication development efforts, no effective pharmacotherapy for cocaine
abuse has demonstrated efficacy for long-term use. Given the obvious importance of the …